China Dasheng Biotechnology Company
CDBTOTCFinancial Services
$0.10
+$0.00(+0.00%)
Market Cap$4097600
P/E Ratio—
52W High$0.15
52W Low$0.0003
China Dasheng Biotechnology Company (CDBT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CDBT · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-06 | 2008-06 | 2007-10 | 2006-10 | 2005-10 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.02B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.01B | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | 46.05% | — | 24.71% | 35.52% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Operating Income | ($0.00B) | $0.01B | ($0.00B) | ($0.00B) | ($0.00B) |
| Operating Margin %(computed) | — | 31.15% | — | -3.48% | -3.61% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | $0.01B | ($0.00B) | $0.00B | ($0.00B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.00B) | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Margin %(computed) | — | 28.46% | — | -3.48% | -3.61% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.02 | $0.15 | $-0.01 | $-0.00 | $-0.00 |
| Wtd Avg Shares | 0.04B | 0.03B | 0.01B | 0.01B | 0.01B |
| EBITDA | ($0.00B) | $0.01B | ($0.00B) | ($0.00B) | ($0.00B) |
| EBITDA Margin %(computed) | — | 34.99% | — | -3.14% | -3.35% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more China Dasheng Biotechnology Company data
About China Dasheng Biotechnology Company (CDBT) Income Statement
China Dasheng Biotechnology Company (CDBT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, CDBT reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
CDBT · 4 questionsChina Dasheng Biotechnology Company (CDBT) reported revenue of $0.00B for 2023, down 100.0% year-over-year.
CDBT revenueCDBT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09